Ge Long Hui·2025-10-14 10:09Core Insights - Fosun Pharma's subsidiary, Fosun Wanguo, has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug SAF-189, an innovative small molecule chemical drug intended for treating non-small cell lung cancer (NSCLC) [1] Group 1 - The drug SAF-189 was initially accepted for registration in March 2025 for treating ALK-positive locally advanced or metastatic NSCLC patients [1] - The withdrawal of the registration application is not a termination of the project; Fosun Wanguo plans to improve the registration materials according to the latest technical requirements from the NMPA and will resubmit the application as soon as possible [1] - The withdrawal of the registration application is not expected to have a significant impact on the current performance of the group, which includes the company and its subsidiaries [1]